We previously demonstrated that a high volume of distribution, a highly immunologically active disease (i.e., high anti-PLA2R1 antibody titer, PLA2R1 epitope spreading, and high interleukine-17A levels), and 25-hydroxyvitamin D deficiency are risk factors for the occurrence of anti-rituximab antibodies in patients with membranous nephropathy.17 The gene discussed is PLA2R1; the disease is membranous glomerulonephritis.